Gene by Gene

GeneByGene.com

The most complete family of integrated multi-disciplinary genetic testing services, with state-of-the-art laboratory and capabilities. Gene by Gene, through its division Family Tree DNA was the first company in the world to develop DNA testing for ancestry and genealogical purposes as a commercial application. Prior to the company’s initiative, these tests were only available for academic and research purposes. Because of this innovation, it was selected by the National Geographic Society and its partner, IBM, to provide the testing and manage all public participation in the Genographic Project. Initially, the Arizona Research Labs at The University of Arizona performed all testing. In 2006, Gene by Gene established a state-of-the-art Genomics Research Center at its headquarters in Houston, Texas, where it currently performs R&D and processes over 200 types of DNA tests for its customers, ranging from individuals to physicians, hospitals, universities and research institutions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

news image

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More

TFF PHARMACEUTICALS AND FELIX BIOTECHNOLOGY SIGN LETTER OF INTENT FOR A COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT

Felix Biotechnology, Inc. | November 06, 2020

news image

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, and Felix Biotechnology, Inc., a clinical stage, biotherapeutic-based antibiotic development company, today jointly announce that both companies have entered into a letter of intent (LOI) which reflects the parties’ non-binding agreement in principle to negotiate and enter ...

Read More

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

news image

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More

MEDTECH

NEUROSENSE THERAPEUTICS AND NEURALIGHT COLLABORATE TO DETECT ALS OCULOMETRIC BIOMARKERS USING AI AND ML

NeuroSense and NeuraLight | July 29, 2022

news image

NeuroSense Therapeutics Ltd. a company developing treatments for severe neurodegenerative diseases, and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis. NeuraLight's platform, uses proprietary computer vision and deep learning algorithms to extract over 100 o...

Read More
news image

INDUSTRIAL IMPACT

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More
news image

TFF PHARMACEUTICALS AND FELIX BIOTECHNOLOGY SIGN LETTER OF INTENT FOR A COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT

Felix Biotechnology, Inc. | November 06, 2020

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, and Felix Biotechnology, Inc., a clinical stage, biotherapeutic-based antibiotic development company, today jointly announce that both companies have entered into a letter of intent (LOI) which reflects the parties’ non-binding agreement in principle to negotiate and enter ...

Read More
news image

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More
news image

MEDTECH

NEUROSENSE THERAPEUTICS AND NEURALIGHT COLLABORATE TO DETECT ALS OCULOMETRIC BIOMARKERS USING AI AND ML

NeuroSense and NeuraLight | July 29, 2022

NeuroSense Therapeutics Ltd. a company developing treatments for severe neurodegenerative diseases, and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis. NeuraLight's platform, uses proprietary computer vision and deep learning algorithms to extract over 100 o...

Read More